Edward G Lakatta Selected Research

Fenoterol

4/2012	Fenoterol enantiomers do not possess beneficial therapeutic properties of their racemic mixture in the rat model of post myocardial infarction dilated cardiomyopathy.
10/2011	β₂ AR agonists in treatment of chronic heart failure: long path to translation.
8/2004	Beneficial effects of chronic pharmacological manipulation of beta-adrenoreceptor subtype signaling in rodent dilated ischemic cardiomyopathy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Edward G Lakatta Research Topics

Disease

27	Hypertension (High Blood Pressure) 10/2021 - 02/2002
15	Heart Failure 12/2020 - 06/2002
15	Myocardial Infarction 10/2012 - 09/2003
14	Fibrosis (Cirrhosis) 11/2019 - 02/2005
12	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 04/2004
11	Inflammation (Inflammations) 01/2021 - 10/2008
9	Infarction (Infarctions) 11/2013 - 03/2004
8	Atherosclerosis 01/2021 - 06/2003
6	Abdominal Obesity 12/2016 - 05/2009
5	Hypertrophy 01/2020 - 02/2005
5	Dilated Cardiomyopathy (Cardiomyopathy, Congestive) 06/2013 - 03/2004
4	Cardiomegaly (Heart Hypertrophy) 01/2020 - 02/2004
4	Metabolic Syndrome (Dysmetabolic Syndrome X) 05/2019 - 04/2005
4	Diabetes Mellitus 08/2017 - 06/2012
3	Vascular Remodeling 04/2022 - 01/2016
3	Ischemia 01/2021 - 10/2005
3	Pre-Eclampsia (Preeclampsia) 08/2018 - 12/2008
3	Heart Diseases (Heart Disease) 03/2017 - 03/2006
3	ST Elevation Myocardial Infarction 11/2013 - 11/2010
3	Ventricular Remodeling 05/2011 - 03/2006
3	Hypoxia (Hypoxemia) 04/2011 - 12/2004
2	COVID-19 01/2021 - 01/2021
2	Obesity 01/2020 - 05/2009
2	Body Weight (Weight, Body) 01/2020 - 07/2014
2	Type 2 Diabetes Mellitus (MODY) 11/2019 - 01/2012
2	Hyperglycemia 01/2019 - 01/2016
2	Vascular Calcification 01/2018 - 11/2012
2	Bradycardia 11/2017 - 12/2012
2	Hyperplasia 01/2016 - 12/2013
2	Hypercholesterolemia 01/2016 - 10/2012
2	Infections 11/2012 - 08/2012
2	Insulin Resistance 01/2012 - 11/2006
1	Cognitive Dysfunction 04/2022
1	Dementia (Dementias) 04/2022
1	Memory Disorders (Memory Loss) 10/2021
1	Alcoholism (Alcohol Abuse) 01/2020
1	Neoplasms (Cancer) 01/2020
1	Fatty Liver 01/2020

Drug/Important Bio-Agent (IBA)

17	marinobufageninIBA 04/2022 - 03/2002
10	SaltsIBA 04/2022 - 08/2011
8	CollagenIBA 11/2019 - 11/2010
8	Adenosine Triphosphatases (ATPase)IBA 11/2019 - 03/2003
8	Triglycerides (Triacylglycerol)IBA 12/2016 - 05/2009
8	Erythropoietin FDA Link 11/2013 - 09/2003
7	LigandsIBA 01/2017 - 03/2002
6	CholesterolIBA 08/2017 - 04/2005
6	Matrix Metalloproteinases (MMPs)IBA 04/2015 - 06/2003
5	Cardiac GlycosidesIBA 04/2022 - 03/2006
5	ATPase Inhibitory ProteinIBA 04/2022 - 01/2008
5	HDL CholesterolIBA 12/2016 - 05/2009
5	Glucose (Dextrose)FDA LinkGeneric 12/2016 - 05/2009
4	LipidsIBA 01/2020 - 07/2007
4	ResveratrolIBA 01/2019 - 11/2006
4	NF-kappa B (NF-kB)IBA 08/2011 - 12/2004
3	oxidized low density lipoproteinIBA 01/2021 - 05/2009
3	Monoclonal AntibodiesIBA 10/2019 - 12/2008
3	Vasoconstrictor AgentsIBA 01/2019 - 02/2002
3	Sodium-Potassium-Exchanging ATPase (Sodium, Potassium ATPase)IBA 01/2017 - 03/2002
3	ElastinIBA 02/2014 - 11/2010
3	Proteins (Proteins, Gene)FDA Link 12/2013 - 06/2012
3	FenoterolIBA 04/2012 - 08/2004
3	CytokinesIBA 03/2012 - 01/2009
3	Angiotensin IIIBA 03/2012 - 06/2003
2	Thyroid HormonesIBA 01/2021 - 05/2019
2	Angiotensin-Converting Enzyme 2IBA 01/2021 - 01/2021
2	Insulin (Novolin)FDA Link 01/2020 - 11/2006
2	Nitroprusside (Sodium Nitroprusside)FDA LinkGeneric 11/2019 - 08/2015
2	Protein Kinases (Protein Kinase)IBA 11/2019 - 12/2004
2	Transforming Growth Factors (Transforming Growth Factor)IBA 11/2019 - 10/2019
2	Sucrose (Saccharose)IBA 01/2019 - 07/2014
2	Biological ProductsIBA 10/2018 - 03/2003
2	Transcription Factors (Transcription Factor)IBA 08/2018 - 01/2009
2	AldosteroneIBA 01/2018 - 06/2010
2	SodiumIBA 11/2013 - 08/2011
2	Peptides (Polypeptides)IBA 06/2013 - 10/2005
2	Pertussis ToxinIBA 11/2012 - 01/2012
2	Matrix Metalloproteinase 2 (Gelatinase A)IBA 11/2012 - 06/2003
2	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 08/2012 - 03/2012
2	Pharmaceutical PreparationsIBA 07/2012 - 04/2012
2	Adrenergic Receptors (Adrenergic Receptor)IBA 04/2012 - 06/2006
2	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 10/2011 - 10/2009
2	Protein Isoforms (Isoforms)IBA 04/2010 - 02/2004
1	Sirtuin 1IBA 01/2021
1	Sirtuin 3IBA 01/2021
1	Immunoglobulin M (IgM)IBA 01/2021
1	Immunoglobulin G (IgG)IBA 01/2021
1	Apolipoproteins E (ApoE)IBA 01/2021
1	AntibodiesIBA 01/2021
1	AngiotensinsIBA 01/2021
1	MicroRNAs (MicroRNA)IBA 12/2020
1	Disulfiram (Antabuse)FDA Link 01/2020
1	Vasodilator Agents (Vasodilators)IBA 11/2019
1	Fibronectins (Fibronectin)IBA 11/2019
1	AdipokinesIBA 05/2019
1	Discoidin Domain Receptor 2IBA 01/2019
1	SteroidsIBA 01/2019
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2019

Therapy/Procedure

11	Therapeutics 01/2016 - 04/2004
10	Ligation 03/2017 - 09/2003
2	Percutaneous Coronary Intervention 05/2011 - 11/2010